FDAnews
www.fdanews.com/articles/198006-osmotica-receives-fda-approval-for-droopy-eyelid-treatment

Osmotica Receives FDA Approval for Droopy Eyelid Treatment

July 10, 2020

The FDA approved Osmotica Pharmaceuticals’ Upneeq (oxymetazoline hydrochloride ophthalmic solution) for treatment of drooping upper eyelids in adults.

The approval makes Upneeq the only FDA-approved treatment for ptosis, a condition that can limit the field of vision.

Osmotica plans to make Upneeq commercially available next month through a select group of ophthalmologists and optometrists.

View today's stories